Optimizing the timing of 3.6 mg Pegfilgrastim Administration for Dose-Dense Chemotherapy in Japanese Patients with Breast Cancer.

Published on Jun 1, 2021in Acta Medica Okayama0.642
· DOI :10.18926/AMO/62231
Daisuke Takabatake13
Estimated H-index: 13
Yukiko Kajiwara2
Estimated H-index: 2
(Okayama University)
+ 15 AuthorsKenjiro Aogi30
Estimated H-index: 30
Perioperative dose-dense chemotherapy (DDCT) with pegfilgrastim (Peg) prophylaxis is a standard treatment for high-risk breast cancer. We explored the optimal timing of administration of 3.6 mg Peg, the dose approved in Japan. In the phase II feasibility study of DDCT (adriamycin+cyclophosphamide or epirubicin+cyclophosphamide followed by paclitaxel) for breast cancer, we investigated the feasibility, safety, neutrophil transition, and optimal timing of Peg treatment by administering Peg at days 2, 3, and 4 post-chemotherapy (P2, P3, and P4 groups, respectively). Among the 52 women enrolled, 13 were aged > 60 years. The anthracycline sequence was administered to P2 (n=33), P3 (n=5), and P4 (n=14) patients, and the taxane sequence to P2 (n=38) and P3 (n=6) patients. Both sequences showed no interaction between Peg administration timing and treatment discontinuation, treatment delay, or dose reduction. However, the relative dose intensity (RDI) was significantly different among the groups. The neutrophil count transition differed significantly among the groups receiving the anthracycline sequence. However, the neutrophil count remained in the appropriate range for both sequences in the P2 group. The timing of Peg administration did not substantially affect the feasibility or safety of DDCT. Postoperative day 2 might be the optimal timing for DDCT.
📖 Papers frequently viewed together
5 Citations
25 Citations
1 Citations
#1Daisuke TakabatakeH-Index: 13
#2Yukiko KajiwaraH-Index: 2
Last. Hiroyoshi Doihara (Okayama University)H-Index: 27
view all 19 authors...
Background Perioperative dose-dense chemotherapy (DDCT) with granulocyte-colony stimulating factor (G-CSF) prophylaxis is a standard treatment for patients with high-risk breast cancer. The approval of this approach in Japan led to the widespread adoption of DDCT, despite limited efficacy and safety data among Japanese patients. We evaluated the efficacy and safety of neoadjuvant DDCT for Japanese patients with breast cancer.
3 CitationsSource
#1Sachi Morita (Nagoya University)H-Index: 6
#2Toyone KikumoriH-Index: 23
Last. Yuichi Ando (Nagoya University)H-Index: 31
view all 15 authors...
Background Dose-dense chemotherapy consisting of a combination of epirubicin and cyclophosphamide (EC) improves the survival of patients with breast cancer. Although pegfilgrastim was used at a subcutaneous dose of 6.0 mg in a pivotal study of dose-dense EC treatment, pegfilgrastim at a dose of 3.6 mg has been approved in Japan. We have assessed the feasibility of dose-dense EC treatment supported with a 3.6 mg dose of pegfilgrastim by evaluating the relative dose intensity (RDI) and safety of t...
5 CitationsSource
BACKGROUND: This retrospective study aimed to evaluate the efficacy of a 3.6-mg dose of pegfilgrastim for primary prophylaxis in Japanese breast cancer patients receiving dose-dense chemotherapy. METHODS: Patients treated with adjuvant or neoadjuvant chemotherapy for early-stage breast cancer at the Tokyo-West Tokushukai Hospital were included in this analysis. Because 6 mg pegfilgrastim has not yet been approved for use in Japan, we compared the outcomes of a dose-dense doxorubicin and cyclopho...
6 CitationsSource
#1Matteo LambertiniH-Index: 32
#2Paolo BruzziH-Index: 83
Last. Lucia Del MastroH-Index: 34
view all 9 authors...
Purpose To evaluate the safest timing of pegfilgrastim administration in dose-dense anthracycline- and taxane-based chemotherapy, three different cohorts of patients enrolled in the Gruppo Italiano Mammella (GIM) 2 study and treated at the coordinating center received pegfilgrastim 24 h (cohort A) or 72 h (cohort B) or 96 h (cohort C) after chemotherapy.
15 CitationsSource
#1Norikazu MasudaH-Index: 55
#2Yutaka Tokuda (Tokai University)H-Index: 32
Last. Kazuo Tamura (Fukuoka University)H-Index: 50
view all 6 authors...
Purpose A phase II, open-label, dose-finding, randomized study was performed to evaluate the recommended dose of pegfilgrastim in Japanese breast cancer patients.
16 CitationsSource
#1Nicole J. Watring (EVMS: Eastern Virginia Medical School)H-Index: 2
#2Thomas W. WagnerH-Index: 1
Last. James J. StarkH-Index: 1
view all 3 authors...
27 CitationsSource
#1Muhammad Arshad (NYMC: New York Medical College)H-Index: 63
#2Karen Seiter (NYMC: New York Medical College)H-Index: 32
Last. Delong Liu (NYMC: New York Medical College)H-Index: 52
view all 7 authors...
41 CitationsSource
#1M. D. GreenH-Index: 1
#2H. Koelbl (MLU: Martin Luther University of Halle-Wittenberg)H-Index: 2
Last. Martine Piccart (Institut Jules Bordet)H-Index: 118
view all 14 authors...
Background: We evaluated the efficacy of a single fixed 6 mg dose of pegfilgrastim (a pegylated version of filgrastim) per cycle of chemotherapy, compared with daily administration of filgrastim, in the provision of neutrophil support. Patients and methods: Patients (n = 157) were randomized to receive either a single 6 mg subcutaneous (s.c.) injection of pegfilgrastim or daily 5 mg/kg s.c. injections of filgrastim, after doxorubicin and docetaxel chemotherapy (60 mg/m 2 and 75 mg/m 2 , respecti...
482 CitationsSource
#1Frankie A. HolmesH-Index: 51
#2Stephen E. Jones (Baylor University)H-Index: 21
Last. B. C. Liang (Amgen)H-Index: 2
view all 16 authors...
Background: Neutropenia is common in patients receiving myelotoxic chemotherapy. Pegfilgrastim, a sustained-duration filgrastim is a once-per-cycle therapy for prophylactic neutrophil support. Patients and methods: Women, treated with four cycles of doxorubicin/docetaxel chemotherapy every 21 days, received pegfilgrastim or filgrastim 24 h after chemotherapy as a single subcutaneous injection per chemotherapy cycle (pegfilgrastim 30, 60 or 100 μg/kg) or daily subcutaneous injections (filgrastim ...
243 CitationsSource
#1Larry Norton (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 125
The proven benefits of adjuvant chemotherapy on disease-free and overall survival in breast cancer can be explained by concepts of cell kill. Interventions which result in greater log kill can be expected to produce improved clinical results. The application of logkill concepts to human breast cancer growth, which appears to follow Gompertzian kinetics, suggests not only that the use of non-cross-resistant drugs is important, but that dose-dense schedules may have an advantage over conventional ...
105 CitationsSource
Cited By0